# Concord Biotech Limited (CONCORDBIO)

> CONCORDBIO closed at ₹1,245.60 on 30 Oct 2026, trailing P/E 46.1, market cap ₹13,031 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Concord Biotech Limited (NSE: CONCORDBIO) closed at ₹1,245.60 on 30 Oct 2026, -18.6% over one year, against a 52-week range of ₹987.00 – ₹1,615.00.

In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹309 cr and net profit of ₹71 cr, a 22.9% net margin; revenue grew 25.1% and profit grew 15.3% year on year.

On four consecutive filed quarters its trailing P/E is 46.1; since 29 May 2025 its own P/E has ranged from 31.2 to 60.8 (median 46.0), and today's reading is higher than 52% of those 351 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 13.6%, ROCE 18.1%, debt-to-equity 0.00, Piotroski F-score 8 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 82% of 63 sector peers; PBT margin higher than 87% of 63 sector peers; ROE higher than 48% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹1,245.60 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -15.8% / +22.6% / -18.6% |
| 52-week low – high | ₹987.00 – ₹1,615.00 |
| Market capitalisation | ₹13,031 cr |
| Trailing P/E | 46.1 |
| Price / book | 6.28 |
| EV / EBITDA | 29.0 |
| Earnings yield | 2.2% |
| TTM EPS | ₹27.00 |
| TTM net profit | ₹282 cr |
| Quarter revenue | ₹309 cr |
| Quarter net profit | ₹71 cr |
| Net margin | 22.9% |
| Revenue growth (YoY) | +25.1% |
| Profit growth (YoY) | +15.3% |
| Return on equity | 13.6% |
| ROCE | 18.1% |
| Debt / equity | 0.00 |
| Current ratio | 6.40 |
| Free cash flow | ₹108 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹15.4 cr |

## Questions

### What is the P/E ratio of Concord Biotech Limited?

Concord Biotech Limited's trailing P/E is 46.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 29 May 2025 its P/E has ranged 31.2–60.8.

### What were Concord Biotech Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Concord Biotech Limited reported revenue of ₹309 cr and net profit of ₹71 cr (consolidated), filed with the exchange on 27 Oct 2026.

### What is Concord Biotech Limited's ROE?

Return on equity is 13.6% based on the balance sheet dated 30 Sept 2026.

### Does Concord Biotech Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.

### What is CONCORDBIO's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, CONCORDBIO traded between ₹987.00 and ₹1,615.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/CONCORDBIO

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._